medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2012, Número 4

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2012; 28 (4)


Frecuencia de los transcriptos BCR-ABL en pacientes cubanos con leucemia mieloide crónica

Amor-Vigil AM, González-Medina Y, Cayado-Gutiérrez N, Martínez-Antuña G

Idioma: Español
Referencias bibliográficas: 25
Paginas: 428-434
Archivo PDF: 96.89 Kb.


FRAGMENTO

El cromosoma Filadelfia (Ph) fue la primera anormalidad cromosómica asociada con una enfermedad maligna específica en humanos: la leucemia mieloide crónica (LMC). Este cromosoma es el resultado de una translocación recíproca, la t(9;22)(q34;q11), que da lugar a la formación del gen híbrido BCR-ABL en el cromosoma Ph.1 Esta es la característica distintiva de los pacientes con LMC y si bien no se reporta en el 100 % de los casos, puede aparecer hasta en el 95 %.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996 Oct;88(7):2375-84.

  2. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med. 1988 Oct;319(15):990-8.

  3. Selleri L, von Linderen M, Hermans A, Meijer D, Torelli G, Grosveld G. Chronic myeloid leukemia may be associated with several bcr/abl transcripts including the acute lymphoid leukemia type 7 kb transcript. Blood. 1990 Mar;75(5):1146-53.

  4. Van der Plas DC, Soekarman D, van Gent AM, Grosveld G, Hagemeijer A. Bcr-abl mRNA lacking abl exon a2 detected by polymerase chain reaction in a chronic myelogenous leukemia patient. Leukemia. 1991 Jun;5(6):457-61.

  5. Páldi-Haris P, Barta A, Lengyel L, Bátai A, Masszi T, Reményi P, et al. Molecular background of a new case of chronic myelogenous leukemia with bcr-abl chimera mRNA lacking the A2 exon. Leukemia. 1994 Oct;8(10):1791.

  6. Polák J, Zemanová Z, Michalová K, Klamová H, Cermák J, Haskovec C. A new case of chronic myeloid leukemia (CML) in myeloid blast crisis with an atypical (b3/a3) junction of the BCR/ABL gene. Leukemia. 1998;12:250.

  7. Moravcová J, Rulcová J, Polák J, Zemanová Z, Klamová H, Haskovec C. CML patient with rare b2a3 (e13a3) variant of BCR-ABL transcript: Complete molecular response to imatinib. Leuk Res 2005 Nov;29(11):1365-6.

  8. Liu L, Tanaka H, Ito K, Kyo T, Ito T, Kimura A. Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3. Am J Hematol. 2003 Dec;74(4):268-72.

  9. Amor AM, Cristo V, González Y, Hernández A, Pavón V, Martínez G. Transcripto BCR-ABL atípico en un paciente con leucemia mieloide crónica. Rev Cubana Hematol Inmunol Hemoter. 2011 Sep;27(3):349-55. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892011000300011&lng=es

  10. Saglio G, Pane F, Gottardi E, Frigeri F, Buonaiuto MR, Guerrasio A, et al. Consistent amounts of acute leukemia-associated P190 bcr/abl transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. Blood. 1996 Feb;87(3):1075-80.

  11. Van Rhee F, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC. p190 BCR/ABL mRNA is expressed at low levels in p210- positive chronic myeloid and acute lymphoblastic leukemias. Blood. 1996 Jun;87(12):5213-7.

  12. Lee MS, LeMaistre A, Kantarjian HM, Talpaz M, Freireich EJ, Trujillo JM, et al. Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction. Blood. 1989 Jun;73(8):2165-70.

  13. Osman EA, Hamad K, Elmula IM, Ibrahim ME. Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients. Genet Mol Biol. 2010 Apr;33(2):229-231.

  14. Yaghmaie M, Ghaffari SH, Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi SA, et al. Frequency of BCR-ABL fusion transcript in Iranian patients with chronic myeloid leucemia. Arch Iran Med. 2008 May;11(3):247-51.

  15. Rosas-Cabral A, Martínez-Mancilla M, Ayala-Sánchez M, Vela-Ojeda J, Bahena- Reséndiz P, Vadillo-Buenfil M, et al. Análisis del tipo de transcrito bcr-abl y su relación con la cuenta plaquetaria en pacientes mexicanos con leucemia mieloide crónica. Gac Méd Méx. 2003 Nov-Dec;139(6):553 9.

  16. Meza Espinoza JP, Gutiérrez M, Vázquez A, Delgado JL, Esparza MA, González JR. Prevalence of the BCR/ABL1 transcripts in Mexican patients with chronic myelogenous leucemia. Rev Invest Clin. 2007 Sept-Oct;59(5):338 41.

  17. Goh HG, Hwang JY, Kim SH, Lee YH, Kim YL, Kim DW. Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR. Transl Res. 2006 Nov;148(5):249-56.

  18. Paz-y-Miño C, Burgos R, Morillo SA, Santos JC, Fiallo BF, Leone PE. BCR ABL rearrangement frequencies in chronic myeloid leucemia and acute lymphoblastic leucemia in Ecuador, South America. Cancer Genet Cytogenet. 2002 Jan;132(1):65-7.

  19. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156-9.

  20. Van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukaemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: Investigation of minimal residual disease in acute leukemia. Leukemia. 1999 Dec;13(12):1901-28.

  21. Eisenberg A, Silver R, Soper L, Arlin Z, Coleman M, Bernhardt B, et al. The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia. Leukemia. 1988 Oct;2(10):642-7.

  22. Reiter E, Greinix HT, Brugger S, Keil F, Rabitsch W, Mannhalter C, et al. Longterm follow-up after allogeneic stem cell transplantation for chronic myelogenous leukemia. Bone Marrow Transplant. 1998 Dec;22(suppl 4):S86-8.

  23. Verschraegen CF, Kantarjian HM, Hirsch-Ginsberg C, Lee MS, O'Brien S, Rios MB, et al. The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations. Cancer. 1995 Sep;76(6):992-7.

  24. Perego RA, Costantini M, Cornacchini G, Gargantini L, Bianchi C, Pungolino E, et al. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukemia. Eur J Cancer. 2000 Jul;36(11):1395-1401.

  25. Prejzner W. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes, and survival in patients with chronic myeloid leukemia. Med Sci Monit. 2002 May;8(5):BR19-7.




2020     |     www.medigraphic.com